Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics was a clinical-stage biotechnology company headquartered in Waltham, Massachusetts. It was formed in 2022 and developed antibody therapies for inflammatory and immunological diseases, with a focus on conditions such as atopic dermatitis, asthma and chronic obstructive pulmonary disease. Its approach was to engineer monoclonal antibodies against validated targets with extended half-lives, aiming to allow less frequent subcutaneous dosing than existing treatments.

The company completed its initial public offering in July 2023 and listed its common stock on the Nasdaq Global Select Market under the symbol APGE. Its early pipeline included APG777 for atopic dermatitis, APG808 for COPD, and the earlier-stage programs APG990 and APG222. Over time its lead program, later given the name zumilokibart, advanced as a half-life-extended antibody directed against interleukin-13, and the company also developed an antibody against thymic stromal lymphopoietin for use in asthma and in combination regimens.

Clinical results from a Phase 2 study in atopic dermatitis showed that about two-thirds of treated patients achieved significant skin clearance at 16 weeks, and longer-term data suggested dosing might be possible every three months or twice a year. These results contributed to a large rise in the share price, which traded in a range of roughly $35 to $135 during the final twelve months of its listing. Apogee remained an independent company without approved products throughout its time as a public company.

In 2026 AbbVie agreed to acquire Apogee for $135.11 per share in cash, an equity value of about $10.9 billion. AbbVie, a large pharmaceutical company listed on the New York Stock Exchange, was seeking to add a late-stage immunology pipeline to its portfolio. AbbVie said that the transaction would reduce its adjusted diluted earnings per share by $0.14 in 2026 and about $0.46 in 2027, and would become accretive in 2032.

The acquisition closed on September 3, 2026. Apogee's shares closed at $135.07 on the last trading day, just below the offer price, and stopped trading on Nasdaq before the market opened on September 3. A Form 25 notice of delisting was filed with the SEC on that date. Apogee became part of AbbVie, and its former shareholders received the cash consideration for each share they held.